Browse News
Filter News
Found 198 articles
-
Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.
-
The annual observance highlights how far the industry has come and serves as a wake-up call for how far it must still go to meet the needs of patients with rare diseases.
-
Despite recent investment and breakthroughs for rare diseases such as Friedreich’s ataxia and progeria, experts say helping patients with rare diseases will require cross-sector support.
-
Patient advocacy groups aided in the development of the very first marketed drugs for certain rare diseases, including progeria and Friedreich’s ataxia.
-
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
2/20/2024
Celcuity Inc., a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced the appointment of Eldon Mayer as Chief Commercial Officer.
-
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
1/18/2024
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).
-
Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work
1/17/2024
Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.
-
LIB Therapeutics Announces Appointment of Ingrid Choong, PhD as Chief Business Officer as Company Prepares BLA for Lerodalcibep
12/7/2023
LIB Therapeutics Inc. announced the appointment of Ingrid Choong, PhD as Chief Business Officer.
-
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.
-
Following cases of hepatobiliary toxicity leading to liver decompensation, Eiger has decided to drop its Phase III LIMT-2 trial of peginterferon lambda in chronic hepatitis delta.
-
Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.
-
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8/14/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today reported financial results for the second quarter 2023 and provided a business update.
-
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
6/29/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications.
-
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2023 and provided a business update.
-
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/16/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update.
-
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
2/8/2023
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM).
-
Allosteric Bioscience Announces the Appointment of Dr. Susan Michaelis to its Scientific Advisory Board
2/7/2023
Allosteric Bioscience, Inc., announced today that Dr. Susan Michaelis has joined its Scientific Advisory Board (SAB).
-
Eiger BioPharmaceuticals Announces Leadership Change
12/15/2022
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, and its Board of Directors announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately.
-
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
12/8/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced topline primary Week 48 data from its landmark Phase 3 D-LIVR study (N=407) evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic HDV: lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (combination).
-
Eiger BioPharmaceuticals to Participate in Upcoming November 2022 Investor Conferences
11/8/2022
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, announced that members of its management team will participate in the following upcoming investor conferences.